ViewRay
Oakwood
About ViewRay
ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery. The company was incorporated in 2004 and is based in Cleveland, Ohio.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $100K – $500K
- Total funding: $877.8M
- Funding stage: IPO
- Last round: Post-IPO Debt (Nov 2022)
- Ticker: nasdaq:VRAY
- Website: viewray.com
- Phone: 440-703-3210
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/viewray-30806 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.